Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Single-center, Single-arm, Open-label Study of Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

NCT06015035 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT06015035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06015035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Single-center, Single-arm, Open-label Study of Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Lead sponsor
Tang-Du Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2021
Completion date
April 1, 2022
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sintilimab and anlotinib in combination with chemotherapy